Retatrutide, a experimental dual agonist of the GLP-1 target and glucose-dependent insulinotropic polypeptide (GIP) target, is showing promising data in preliminary clinical assessments . Current inquiry https://bookmarktiger.com/story21313469/retatrutide-emerging-studies-and-potential-clinical-roles